These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30027395)

  • 41. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
    Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polycythemia Vera: Rapid Evidence Review.
    Fox S; Griffin L; Robinson Harris D
    Am Fam Physician; 2021 Jun; 103(11):680-687. PubMed ID: 34060791
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.
    Kuykendall AT
    Ann Hematol; 2023 May; 102(5):985-993. PubMed ID: 36944847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent advances in the treatment of polycythemia vera.
    Duek A; Berla M; Ellis MH
    Leuk Lymphoma; 2022 Aug; 63(8):1801-1809. PubMed ID: 35387553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
    Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
    Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel germline JAK2
    Song J; Lanikova L; Kim SJ; Papadopoulos N; Meznarich J; Constantinescu SN; Parsegov B; Prchal JF; Prchal JT
    Am J Hematol; 2024 Jul; 99(7):1220-1229. PubMed ID: 38629639
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New Therapeutic Approaches in Polycythemia Vera.
    Falchi L; Newberry KJ; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S27-33. PubMed ID: 26297275
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
    Nazha A; Khoury JD; Verstovsek S; Daver N
    Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ruxolitinib for the treatment of patients with polycythemia vera.
    Kiladjian JJ; Winton EF; Talpaz M; Verstovsek S
    Expert Rev Hematol; 2015 Aug; 8(4):391-401. PubMed ID: 25980454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How to manage polycythemia vera.
    Passamonti F
    Leukemia; 2012 May; 26(5):870-4. PubMed ID: 22157736
    [TBL] [Abstract][Full Text] [Related]  

  • 55. JAK2-positive Philadelphia-negative myeloproliferative neoplasms.
    Sharma A; Buxi G; Marwah S; Yadav R
    Indian J Pathol Microbiol; 2011; 54(1):117-20. PubMed ID: 21393891
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Recent advances in polycythemia vera treatment].
    Edahiro Y
    Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post-JAK2 V617F Discovery Era.
    Kander EM; Moliterno AR; Rademaker A; Streiff MB; Spivak JL; Stein BL
    J Natl Compr Canc Netw; 2016 Oct; 14(10):1238-1245. PubMed ID: 27697978
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.
    Ebid GT; Ghareeb M; Salaheldin O; Kamel MM
    Int J Clin Exp Pathol; 2015; 8(9):11555-9. PubMed ID: 26617890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment of polycythemia vera].
    Dulíček P
    Vnitr Lek; 2018; 64(10):955-960. PubMed ID: 30590943
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera].
    Roche-Lestienne C; Andrieux J
    Pathol Biol (Paris); 2007 Feb; 55(1):49-55. PubMed ID: 16901657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.